5% Off
Carboplat10 mg/ml
Beacon Pharmaceuticals PLC
৳1330.00
Add to cart
Generic medicine
Carboplatin: Brands, Price & Uses in Bangladesh
Carboplatin is a platinum-based chemotherapy agent used in the treatment of certain cancers, primarily as part of physician-supervised combination or single-agent regimens.
About Carboplatin
Indications of Carboplatin
Carboplatin is a platinum-based chemotherapy agent used in the treatment of certain cancers, primarily as part of physician-supervised combination or single-agent regimens.
Established / FDA-approved uses
- Initial treatment of advanced ovarian carcinoma — Carboplatin is indicated, in combination with other approved chemotherapeutic agents (commonly cyclophosphamide), for the initial treatment of advanced epithelial ovarian carcinoma.
- Palliative treatment of recurrent ovarian carcinoma — Carboplatin is indicated as secondary/palliative therapy for patients with ovarian carcinoma recurrent after prior chemotherapy, including patients previously treated with cisplatin.
Guideline-supported / commonly used off-label uses
Carboplatin is widely used, based on strong clinical evidence and inclusion in oncology treatment guidelines, in combination regimens (often with a taxane such as paclitaxel) for:
- Non-small cell lung cancer (NSCLC)
- Small cell lung cancer (SCLC)
- Head and neck squamous cell carcinoma
- Cervical cancer
- Endometrial cancer
- Bladder (urothelial) cancer
- Triple-negative breast cancer (in select combination regimens)
- Germ cell tumors and certain pediatric malignancies (e.g., retinoblastoma, brain tumors), used under specialist pediatric oncology protocols
These non-ovarian uses are considered off-label relative to the original approved labeling but are standard of care in many oncology guidelines and must only be prescribed by an oncologist.
Dosage & Administration of Carboplatin
Carboplatin must be administered by intravenous infusion, under the supervision of a physician experienced in cancer chemotherapy. Dosing is highly individualized and commonly calculated using the Calvert formula, based on the patient's renal function (glomerular filtration rate, GFR) and a target area-under-curve (AUC):
Total Dose (mg) = Target AUC (mg/mL·min) × (GFR + 25)
| Indication / Regimen | Typical Adult Dosing |
|---|---|
| Single-agent therapy (previously untreated) | 360 mg/m² IV once every 4 weeks, or AUC-based dosing (target AUC typically 5-7 mg/mL·min) |
| Combination therapy with cyclophosphamide (advanced ovarian carcinoma) | 300 mg/m² IV once every 4 weeks for 6 cycles, in combination with cyclophosphamide 600 mg/m² |
| Combination regimens (e.g., with paclitaxel, for various solid tumors, off-label) | AUC 5-6 mg/mL·min IV once every 3-4 weeks, per specific oncology protocol |
Dose adjustment based on hematologic toxicity (subsequent courses)
| Platelet count | Neutrophil count | Dose adjustment |
|---|---|---|
| >100,000/mm³ | >2,000/mm³ | 125% of prior course dose |
| 50,000-100,000/mm³ | 500-2,000/mm³ | No adjustment (100% of prior dose) |
| <50,000/mm³ | <500/mm³ | 75% of prior course dose |
Renal impairment dosing
Renal function markedly affects Carboplatin clearance; the Calvert formula inherently adjusts for this, but general starting-dose guidance for single-agent use in adults with reduced renal function has included creatinine clearance 41-59 mL/min: approximately 250 mg/m² IV; creatinine clearance 16-40 mL/min: approximately 200 mg/m² IV. Patients with creatinine clearance below 15 mL/min are not well studied; use requires extreme caution and specialist oncology/nephrology input.
Administration
Carboplatin is administered only as a slow intravenous infusion, typically over 15-60 minutes, after dilution in 5% dextrose or 0.9% sodium chloride. Do not use needles or IV administration sets containing aluminum parts, as aluminum reacts with Carboplatin causing precipitate formation and loss of potency. Antiemetic premedication is standard practice before administration, as Carboplatin is highly emetogenic. Only healthcare professionals trained in handling cytotoxic drugs should prepare and administer Carboplatin.
See Pediatric Use and Use in Special Populations for further detail.
Side Effects of Carboplatin
Carboplatin commonly causes dose-related adverse effects, most notably on the bone marrow and gastrointestinal system.
Very common
- Myelosuppression: thrombocytopenia (dose-limiting), neutropenia, leukopenia, anemia (may require transfusion)
- Nausea and vomiting (often severe without antiemetic prophylaxis)
- Electrolyte disturbances (hyponatremia, hypokalemia, hypocalcemia, hypomagnesemia)
- Fatigue, asthenia
Common
- Peripheral neuropathy (more frequent in patients over 65 years or those pretreated with cisplatin)
- Ototoxicity (hearing impairment, tinnitus)
- Elevated liver enzymes
- Alopecia (less common than with some other chemotherapy agents)
- Infection (secondary to neutropenia)
Serious / rare
- Anaphylactic-like hypersensitivity reactions (can occur within minutes of administration; more common with repeated courses) — see Precautions and Warnings.
- Hemorrhage related to severe thrombocytopenia
- Visual disturbances, including rare reports of loss of vision, generally with doses higher than recommended
- Hemolytic uremic syndrome (rare)
- Secondary malignancies (rare, with long-term use)
Contraindications of Carboplatin
Carboplatin is contraindicated in patients with:
- Known severe hypersensitivity to Carboplatin, other platinum-containing compounds (e.g., cisplatin), or mannitol.
- Severe, pre-existing bone marrow suppression.
- Significant active bleeding.
Frequently Asked Questions about Carboplatin
What is Carboplatin used for?
Carboplatin is a chemotherapy medicine most commonly used to treat advanced ovarian cancer, often combined with other chemotherapy drugs. It is also used, often off-label but per standard oncology guidelines, for lung cancer, head and neck cancer, cervical cancer, and several other solid tumors, always under the care of a cancer specialist.
How is Carboplatin given?
Carboplatin is given only as a slow intravenous (IV) infusion in a hospital or cancer treatment center by trained healthcare staff. It cannot be taken by mouth or given as an injection at home. Your dose is carefully calculated based on your kidney function using a formula (the Calvert formula) and your target treatment goal.
What are the most important side effects of Carboplatin to watch for?
Carboplatin commonly lowers blood cell counts (platelets, white blood cells, and red blood cells), which can increase your risk of bleeding, infection, and fatigue/anemia. Nausea and vomiting are also common, so anti-nausea medicine is usually given beforehand. Rarely, allergic reactions can occur within minutes of the infusion — tell your care team immediately if you notice swelling, wheezing, dizziness, or a fast heartbeat during or shortly after your infusion.
Can Carboplatin be used during pregnancy or breastfeeding?
Carboplatin can harm an unborn baby and should generally be avoided during pregnancy, especially in the first trimester. It should only be used in pregnancy if clearly necessary and if your oncologist decides the benefit outweighs the risk. Breastfeeding should be stopped during treatment with Carboplatin, as it is not known whether it passes into breast milk, and infant exposure could be harmful.
Are there absolute reasons someone should not receive Carboplatin?
Yes. Carboplatin should not be given to anyone with a known severe allergy to Carboplatin, other platinum-based chemotherapy drugs (like cisplatin), or mannitol, or to patients who already have severe bone marrow suppression or significant active bleeding.
What happens if too much Carboplatin is given (overdose)?
An overdose of Carboplatin can cause severe and prolonged suppression of blood cell production, increasing the risk of serious infection and bleeding, along with possible liver, hearing, or vision problems. If an overdose is suspected, seek immediate medical attention or go to the emergency room right away; treatment involves close hospital monitoring and supportive care.
Disclaimer
The information provided is accurate to the best of our knowledge, but it does not replace professional medical advice. We cannot guarantee its completeness or accuracy, and the absence of specific information about a drug should not be taken as an endorsement. We are not responsible for any consequences arising from this information, so please consult a healthcare professional for any concerns or questions.